Maria A. Carmona-Gonzalez

Sigmund Freud Str. 25
Bonn, NW 53127, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 84 publications

The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors.

The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors.

Journal: ESMO gastrointestinal oncology

Published: August 12, 2026

Early C-reactive protein kinetics predict outcomes in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors: a multicenter, observational study comparing different C-reactive protein kinetic definitions.

Early C-reactive protein kinetics predict outcomes in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors: a multicenter, observational study comparing different C-reactive protein kinetic definitions.

Journal: Frontiers in oncology

Published: June 02, 2026

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.

Journal: The Lancet. Oncology

Published: May 08, 2026

Prognostic Significance of CD68+ Macrophages and FoxP3+ Regulatory T Cells in Neuroendocrine Tumors.

Prognostic Significance of CD68+ Macrophages and FoxP3+ Regulatory T Cells in Neuroendocrine Tumors.

Journal: Nuklearmedizin. Nuclear medicine

Published: December 01, 2025

Psycho-Oncological Screening Identifies High-Risk Subgroups Among Neuroendocrine Tumor Patients Undergoing PRRT with [177Lu]Lu-DOTATATE: Implications for Survival.

Psycho-Oncological Screening Identifies High-Risk Subgroups Among Neuroendocrine Tumor Patients Undergoing PRRT with [177Lu]Lu-DOTATATE: Implications for Survival.

Journal: Nuklearmedizin. Nuclear medicine

Published: June 30, 2025

Improved Implementation of Tumor Board Decisions: A Retrospective Single Center Observational Study in Germany.

Improved Implementation of Tumor Board Decisions: A Retrospective Single Center Observational Study in Germany.

Journal: In vivo (Athens, Greece)

Published: June 10, 2025

Clinical practice and implications of biomarker testing in biliary tract cancer: An observational study.

Clinical practice and implications of biomarker testing in biliary tract cancer: An observational study.

Journal: JHEP reports : innovation in hepatology

Published: May 29, 2025

Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).

Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).

Journal: Therapeutic advances in medical oncology

Published: March 31, 2025

The IL-6/JAK/STAT3 Axis in Cholangiocarcinoma and Primary Sclerosing Cholangitis: Unlocking Therapeutic Strategies Through Patient-Derived Organoids.

The IL-6/JAK/STAT3 Axis in Cholangiocarcinoma and Primary Sclerosing Cholangitis: Unlocking Therapeutic Strategies Through Patient-Derived Organoids.

Journal: Biomedicines

Published: March 13, 2025

Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study.

Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study.

Journal: Cancers

Published: February 03, 2025

The Antibody-Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma.

The Antibody-Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma.

Journal: Molecular cancer therapeutics

Published: October 28, 2024

Efficacy and safety of neoadjuvant FLOT treatment for resectable gastric/gastroesophageal junction adenocarcinoma in Turkish and German patients; a real-world data.

Efficacy and safety of neoadjuvant FLOT treatment for resectable gastric/gastroesophageal junction adenocarcinoma in Turkish and German patients; a real-world data.

Journal: BMC cancer

Published: October 25, 2024

Showing 1-12 of 84

Last Updated: 09/26/2026